title: Melphalan, Antimelanoma Immunity, and Inflammation--Response.
authors.affiliation: Cell Death Research and Therapy (CDRT) Lab, Department of Cellular Molecular Medicine, KU Leuven University of Leuven, Leuven, Belgium.
authors.forename: Abhishek D
authors.initials: AD
authors.lastname: Garg
authors.affiliation: Cell Death Research and Therapy (CDRT) Lab, Department of Cellular Molecular Medicine, KU Leuven University of Leuven, Leuven, Belgium.
authors.forename: Aleksandra M
authors.initials: AM
authors.lastname: Dudek-Peric
authors.affiliation: Cell Death Research and Therapy (CDRT) Lab, Department of Cellular Molecular Medicine, KU Leuven University of Leuven, Leuven, Belgium. patrizia.agostinis@med.kuleuven.be.
authors.forename: Patrizia
authors.initials: P
authors.lastname: Agostinis
mesh_terms: D000818:Animals; D000954:Antigens, Surface / Q000502:physiology*; D018906:Antineoplastic Agents, Alkylating / Q000494:pharmacology*; D037282:Calreticulin / Q000502:physiology*; D006801:Humans; D008545:Melanoma / Q000276:immunology*; D008558:Melphalan / Q000494:pharmacology*; D012878:Skin Neoplasms / Q000276:immunology*
chemical_list: D000954:Antigens, Surface; D018906:Antineoplastic Agents, Alkylating; D037282:Calreticulin; D008558:Melphalan